Ketamine
Viewing r1 — Apr 20, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Ketamine — special K, ket, vitamin K — is a synthetic dissociative of the arylcyclohexylamine class. It is a shorter-acting derivative of phencyclidine (PCP), known for its unusual clinical safety and versatility. It blocks glutamate signaling in the brain,[1] producing a progressive disconnection from sensory reality.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
phencyclidine, methoxetamine, deschloroketamine +2 morephencyclidine, methoxetamine, deschloroketamine, 2-fluorodeschloroketamine, nitrous oxide show less
First synthesized by Calvin Stevens in 1962 and approved as a surgical anesthetic in 1970, ketamine became a battlefield medicine in Vietnam before entering recreational and psychiatric use.[2] A landmark 2006 trial showed it could reverse treatment-resistant depression within hours — reshaping psychiatric pharmacology.[3] It is now a Schedule III substance in the United States, with esketamine (Spravato) approved for depression in 2019.[4]
Subjective effects include depersonalization, derealization, bodily dissociation, time alteration, and analgesia. The experience is one of progressive disconnection — sensory input arrives but fails to cohere, producing a floating detachment that deepens toward complete severance from external reality at higher doses. Nausea, confusion, amnesia, and motor impairment are characteristic unsought effects.
Psychological dependence is high — short duration encourages compulsive redosing, and ketamine activates dopamine reward circuits;[5][6] sole-agent fatality is rare.[7] Chronic use causes devastating bladder damage, liver injury, and cognitive decline;[8][9] combining with opioids or depressants is the primary cause of death.[10] Six decades of clinical research make it one of the most thoroughly studied psychoactive substances.
History[edit]
Discovery
Ketamine was developed as a safer replacement for phencyclidine (PCP), which caused severe psychiatric adverse effects in anesthetic patients. Calvin Stevens synthesized the compound in 1962.[2] The first human trial in 1964 produced a novel state — profound analgesia with preserved reflexes — that Edward Domino's wife named "dissociative anesthesia".[2]
Clinical and scientific significance
FDA approval followed in 1970, and ketamine was immediately deployed in Vietnam as a field anesthetic, valued for its cardiovascular stability and wide safety margin.[2] In the 1980s, researchers established that it worked by blocking glutamate receptors.[1] A 2006 clinical trial then showed ketamine could reverse treatment-resistant depression within hours, opening an entirely new direction in psychiatric medicine.[3]
Recreational use and regulation
Recreational use began in the late 1970s, spread through rave and club culture in the 1980s and 1990s, and prompted US DEA scheduling as Schedule III in 1999.[2] The discovery of ketamine-induced bladder damage in 2007 permanently changed the chronic risk picture,[8] and the UK upgraded it from Class C to Class B in 2015. FDA approval of esketamine (Spravato) for depression in 2019 expanded its medical reach.[4]
The name "ketamine" comes from its molecular components: ketone + amine. Street names — "K," "special K," "vitamin K," "ket" — reflect ubiquity rather than any particular mythology. Unlike psychedelics tied to spiritual traditions, ketamine's cultural identity formed in electronic music scenes and clinical waiting rooms — two worlds that share little except the compound. The "K-hole" — complete dissociative immersion at high doses — entered drug culture vocabulary in the 1990s and remains its most recognizable experiential landmark.
Chemistry[edit]
Structural class
Ketamine belongs to the arylcyclohexylamine family — derived from phencyclidine (PCP) by modifying the ring structure and adding a ketone group, shortening its duration from hours to minutes while preserving the core blocking mechanism. Its molecular formula is C₁₃H₁₆ClNO (237.72 g/mol).
Two mirror-image forms exist: S-ketamine (esketamine, approved as Spravato) is approximately 4× more potent as an anesthetic,[11] while R-ketamine is less active at glutamate receptors[12] and under investigation as a next-generation antidepressant.
Pharmacology[edit]
Mechanism of action
Ketamine blocks glutamate receptors by entering the ion channel while it is open.[1] The blockade intensifies in the most active circuits, cutting communication between brain regions and producing the dissociative state.
At lower doses, blocking inhibitory neurons releases a flood of glutamate into the prefrontal cortex.[13] This drives both psychedelic-like effects and rapid antidepressant action — rebuilding stress-damaged connections within hours.[14][15] A metabolite (hydroxynorketamine) contributes through independent receptor activation,[16] and opioid system engagement also appears necessary for the antidepressant response.[17]
Pharmacokinetics
Bioavailability depends on route: intravenous is complete, intramuscular approximately 93%, intranasal approximately 50%,[4] and oral only 17–26% because the liver breaks down most of it before it reaches the brain.[18][19] The liver converts ketamine to norketamine and hydroxynorketamine (HNK).[11][20] Rifampicin reduces oral ketamine effects by up to 86%;[21] enzyme inhibitors may intensify and prolong them.
Neuroscience[edit]
Where it acts
Ketamine disrupts the connection between the thalamus (the brain's sensory relay) and the cortex (where information is processed). Sensory signals still arrive but fail to integrate[1] — producing the experience of receiving fragments without meaning. At lower doses, silencing inhibitory neurons floods the prefrontal cortex with glutamate,[13] driving cognitive disruption and rapid synapse rebuilding.[14][15]
Why it matters
Ketamine proved that depression could be reversed in hours rather than weeks. NMDA blockade triggers a glutamate surge that activates growth pathways, rebuilding stress-damaged synapses in the prefrontal cortex.[14] A metabolite (hydroxynorketamine) may independently sustain these effects,[16] and opioid system engagement also appears necessary for the antidepressant response.[17]
Why does a drug with a 2–3 hour half-life produce antidepressant effects lasting days to weeks? The growth of new brain connections offers a structural explanation, but the full picture remains incomplete. Primate studies show permanent brain cell death in the prefrontal cortex after 6 months of use,[9] and human chronic users show cognitive impairment resembling schizophrenia,[22] though separating drug effects from confounders is difficult.
Subjective Effects[edit]
Ketamine dissolves the ordinary relationship between self and world. At low doses, the body feels remote, sounds flatten, and a weightless floating quality dominates. As dose increases, the experience shifts qualitatively — coherent selfhood fragments, spatial orientation collapses, and the external world vanishes entirely into abstract internal space.
Within its class, ketamine sits between nitrous oxide — brief and relatively shallow — and PCP, which is longer and far more unpredictable. It is more controllable than MXE and more amnestic than nitrous oxide. Quiet, dark environments facilitate depth; stimulating surroundings tend to produce confusion rather than immersive exploration.
Effect Grid
At common doses, the characteristic dissociative experience fully manifests: significant depersonalization and derealization, time distortion, and perceptual distortions including visual drifting, auditory distortions, and altered depth perception. Thought connectivity changes dramatically — internal experiences become vivid and absorbing. Euphoria is frequently reported, alongside a sense of profound meaningfulness.
Physically, pronounced analgesia, significant motor impairment (difficulty walking), nystagmus, and muscle relaxation are universal. Speech becomes markedly impaired. Nausea is possible but less common than with serotonergic psychedelics.
Ambulation is unsafe at this range. The experience typically demands full surrender to the dissociative state for 45-90 minutes (IV/IM/insufflated) or 2-3 hours (oral).
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Perspective distortion · Proprioceptive distortion · Vestibular distortion · Holotropic state · Sensory deprivation · Visual acuity suppression · Music enhancement · Visual haze / noise · Auditory suppression · Visual drifting · Auditory misinterpretation · Geometry · Peripheral vision distortion · Color alteration · Tracers · Visual morphing · Synesthesia · Dreaming enhancement · Visual processing suppression · Internal hallucinations · Auditory hallucinations · Environmental orbism / cubism · Object transformations · Perspective hallucinations · Visual scenery slicing · External hallucinations · Visual recursion · Gustatory hallucination
Sensory deprivation · Visual acuity suppression · Music enhancement · Visual haze / noise · Auditory suppression · Visual drifting · Auditory misinterpretation · Geometry · Peripheral vision distortion · Color alteration · Tracers · Visual morphing · Synesthesia · Dreaming enhancement · Visual processing suppression · Internal hallucinations · Auditory hallucinations · Environmental orbism / cubism · Object transformations · Perspective hallucinations · Visual scenery slicing · External hallucinations · Visual recursion · Gustatory hallucination
Body high · Nystagmus (eye wobbles) · Spontaneous body sensations · Bodily lightness · Pupil dilation · Dizziness · Physical fatigue · Nausea · Stimulation · Abnormal heartbeat · Salivation · Sexual arousal suppression · Heart rate perception changes · Muscle relaxation · Nasal congestion · Respiratory stimulation · Dehydration sensation · Breathing alteration · Dry mouth · Headache · Laughter fits · Temperature dysregulation · Tingling / electric sensations · Vibrations / buzzing · Tactile euphoria · Involuntary body movements · Restlessness · Trembling · Vomiting · Increased urination · Bodily dissociation · Tactile hallucination
Bodily lightness · Pupil dilation · Dizziness · Physical fatigue · Nausea · Stimulation · Salivation · Sexual arousal suppression · Heart rate perception changes · Muscle relaxation · Nasal congestion · Respiratory stimulation · Dehydration sensation · Breathing alteration · Dry mouth · Headache · Laughter fits · Temperature dysregulation · Tingling / electric sensations · Vibrations / buzzing · Tactile euphoria · Involuntary body movements · Restlessness · Trembling · Vomiting · Increased urination · Bodily dissociation · Tactile hallucination
Thought disorganization · Confusion · Analysis suppression · Information processing suppression · Memory fragmentation · Thought deceleration · Pattern recognition suppression · Language suppression · Immersion enhancement · Introspection enhancement · Conceptual thinking · Cognitive euphoria · Compulsive redosing urge · Cognitive fatigue · Cognitive flexibility · Motivation suppression · Openness enhancement · Thought loops · Creativity enhancement · Humor enhancement · Cognitive dysphoria · Amnesia · Delusions · Delirium
Information processing suppression · Memory fragmentation · Thought deceleration · Pattern recognition suppression · Language suppression · Immersion enhancement · Introspection enhancement · Conceptual thinking · Cognitive euphoria · Cognitive fatigue · Cognitive flexibility · Motivation suppression · Openness enhancement · Thought loops · Creativity enhancement · Humor enhancement · Cognitive dysphoria · Amnesia · Delusions · Delirium
Emotional enhancement · Anxiety · Emotional lability · Emotional suppression · Catharsis · Dysphoria · Irritability
Catharsis · Dysphoria · Irritability
Disinhibition · Sociability suppression · Craving · Compulsive behavior reduction · Ego inflation · Cognitive disconnection · Ego dissolution · Identity alteration · Boundary dissolution
Ego inflation · Cognitive disconnection · Ego dissolution · Identity alteration · Boundary dissolution
Death-rebirth sequence · Entity contact · Existential realization · Noetic insight · Non-dual awareness · Transpersonal visions
Non-dual awareness · Transpersonal visions
Timeline
First effects emerge 15-30 minutes after ingestion: subtle mood shift, mild warmth, and early hints of dissociation as ketamine and norketamine begin reaching active concentrations.
Dissociation builds gradually over 15-30 minutes. The oral come-up is gentler than insufflated, with progressive deepening rather than rapid onset. Analgesia and motor impairment develop.
Maximum intensity sustained 45-90 minutes. Norketamine contributes significantly to the oral peak, producing a somewhat warmer, less sharp dissociative character than parenteral routes.
Extended plateau phase (45-90 minutes) due to sustained norketamine and HNK metabolite activity. Dissociation gradually lightens while dreamy cognitive quality persists.
Effects gradually resolve over 30-60 minutes. Motor function returns. Mild residual dissociation and analgesia taper.
Residual effects from active metabolites (norketamine, HNK) may persist 2-8 hours as subtle mood effects, mild cognitive blunting, or perceptual softness. Antidepressant effects may emerge during this period.
⚠ Do not drive or operate machinery until the following day, as metabolite-mediated impairment outlasts subjective awareness of primary effects.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- High
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 4 weeks
- Physical
- Moderate
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- phencyclidine · methoxetamine · deschloroketamine
Toxicity
Acute toxicity
Ketamine has a wide margin between anesthetic and lethal doses. Unlike most anesthetics, it preserves airway reflexes and cardiovascular stability, producing mild blood pressure elevation rather than depression.[11][7] Sole-agent death is documented but extremely rare; virtually all ketamine-related fatalities involve combination with opioids or other depressants.[10]
No human lethal dose has been established. Death from ketamine alone is mechanistically difficult — the primary risks are choking on vomit or sustaining injury while consciousness is impaired.
Urinary tract damage (chronic)
Ketamine-induced bladder damage is the most significant chronic toxicity in regular users. Frequent use increases cystitis risk 3–4×.[23] End-stage contracted bladder may be irreversible.[24]
Regular use damages the bladder lining through direct cell death,[25] toxic metabolites,[26] and disruption of bladder muscle.[27] Symptoms include urinary urgency, pain, and blood in urine. Early damage may improve with complete cessation; advanced disease — a shrunken, scarred bladder — requires surgical reconstruction.[24]
Liver and bile duct damage (chronic)
Chronic use can inflame bile ducts,[28] cause bile duct dilation,[29] and damage liver cells directly.[30][31] Even repeated clinical infusions can raise liver enzymes.[30] Liver markers typically normalize within 2 months of stopping.
Brain damage (chronic)
Six months of sub-anesthetic ketamine in primates causes permanent brain cell death in the prefrontal cortex.[9] Human chronic users show memory loss and cognitive profiles resembling schizophrenia.[22][32] Some changes partially reverse with abstinence.[1]
Psychological risks
Ketamine produces dose-related psychosis-like symptoms: perceptual distortions, paranoia, and social withdrawal.[33] In people with schizophrenia, 70% experienced worsening symptoms at sub-anesthetic doses.[33] These effects resolve within 30 minutes of a single dose.
Heavy chronic use can trigger persistent psychotic symptoms in a minority of users. Vivid hallucinations, delirium, and confusion during recovery from anesthetic doses are also characteristic.
Tolerance and dependence
Tolerance develops through changes in glutamate receptor density and signaling. Cross-tolerance exists with other NMDA-blocking dissociatives: PCP, MXE, deschloroketamine, 2-FDCK, and nitrous oxide. Extended abstinence is required for reversal.
Psychological dependence liability is high.[6] Short duration, immediate reward, and dopamine activation[5] create a pattern prone to compulsive use; opioid receptor engagement may add to the reinforcement.[17] Physical withdrawal is distressing but not life-threatening,[34] involving dysphoria, cravings, and disrupted sleep.[35]
Drug interactions
The most dangerous combinations suppress breathing and consciousness together.
Opioids (potentially lethal): Ketamine alone preserves breathing; combined with opioids, the respiratory effects add together — the primary cause of ketamine-related death.[10]
GHB/GBL and alcohol (potentially lethal): Both depress consciousness; combined with ketamine, the risk of choking while unconscious increases substantially.
CYP3A4/CYP2B6 interactions: Rifampicin and similar drugs reduce oral ketamine's effectiveness by up to 86%;[21] enzyme inhibitors may prolong and intensify effects.
MAOIs: Ketamine does not cause serotonin syndrome with MAOIs. Blood pressure elevation is a theoretical concern but appears minimal in practice.citation needed
Contraindications
- Uncontrolled high blood pressure or severe heart disease: Ketamine's stimulant-like cardiovascular effects add further stress[11][7]
- History of psychosis or schizophrenia: 70% of patients with schizophrenia experienced worsening symptoms in controlled studies[33]
- Pre-existing bladder disease: Risk of accelerated damage in already-compromised tissue
- Active liver disease: Altered metabolism and increased toxicity risk[30]
- Overactive thyroid: Additive cardiovascular stimulation
- Pregnancy: Precautionary exclusionsafety citation needed
- Co-administration with opioids or depressants: Primary mechanism of ketamine-related death[10]
Harm Reduction[edit]
Forms & Identification
Pharmaceutical-grade liquid (clear, odorless, from sealed vials) offers better purity assurance than dried powder. Powder encountered in unregulated markets has been evaporated from liquid — a process that may concentrate impurities or introduce contaminants.
Reagent testing confirms identity but not purity or dose. Quantitative testing (FTIR or lab analysis via services like WEDINOS or DrugsData) provides the strongest confidence. Fentanyl test strips are worth using given contamination patterns in stimulant and depressant markets, though fentanyl adulteration of ketamine remains less common.
Guidelines
- Test every batch. Reagent testing confirms identity; quantitative analysis confirms dose.
- Weigh doses precisely. The transition from pleasant to overwhelming spans a narrow range. A milligram scale (0.001g) is essential for insufflated powder.
- Start low with new batches. Potency varies between sources; take a threshold dose first.
- Time redoses carefully. Short duration encourages compulsive redosing — the primary dependence pathway. Set a firm limit before starting and use timers.
- Separate ketamine sessions. Regular use causes cumulative bladder damage. Spacing sessions by at least 1–2 weeks and ideally longer reduces chronic harm.
- Eat lightly or fast beforehand. Nausea and vomiting risk increases with stomach contents; choking risk exists at high doses when unconscious.
- Avoid mixing with depressants. Opioids, alcohol, GHB/GBL, and benzodiazepines compound respiratory depression and choking risk.
- Stay hydrated. Adequate water intake may help protect the urinary tract during and after use.
Set & Setting
Ketamine's dissociative character makes environment unusually important. A quiet, comfortable space — dim lighting, familiar surroundings, soft surfaces — supports immersive, controllable experiences. Stimulating or unfamiliar environments increase confusion and physical risk during motor impairment.
A sober companion is strongly recommended at doses approaching or exceeding the K-hole threshold. Complete disconnection from external reality means the person cannot respond to environmental dangers. Physical safety — no heights, no water, recovery position if lying down — matters more than psychological reassurance at dissociative depths.
Aftercare & integration. Ketamine's dissociative depth can produce experiences that feel profoundly meaningful, bizarre, or disturbing. Processing is appropriate regardless of whether the experience was sought therapeutically or recreationally.
In the hours after: gentle re-grounding through familiar sensory input (warm drinks, soft textures, quiet conversation), light food, and rest. Motor coordination and judgment may remain subtly impaired for several hours beyond perceived sobriety. Avoid driving or complex decisions.
For intense or difficult experiences: writing or drawing the experience within 24 hours helps integration before memory fades. Persistent derealization, emotional flatness, or intrusive memories lasting more than a few days warrant professional support — particularly from therapists familiar with dissociative states.
Recovery & Support
Ketamine dependence develops insidiously. The pattern — short duration, immediate reward, easy redosing — can escalate from occasional to daily use without a clear threshold moment. Early signs include dose escalation, using alone, prioritizing supply, and urinary symptoms.
Tapering with professional support is more effective than abrupt cessation for heavy users. Withdrawal involves significant psychological distress — cravings, low mood, insomnia, and cognitive fog that may persist for weeks — but is not physically dangerous.
Specialist support includes drug and alcohol services experienced with dissociative dependence, peer support communities, and urology referral for urinary damage. Bladder symptoms should prompt immediate medical attention and complete cessation; early-stage damage can still recover, but continued use after symptom onset dramatically worsens prognosis.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Unconsciousness with vomiting (choking risk)
- Blue or grey lips/fingernails (oxygen deprivation)
- Extremely slow or stopped breathing
- Seizure
- Chest pain or irregular heartbeat
- Severe confusion with self-harm behavior
An immobile person in a K-hole who is breathing normally and not vomiting is uncomfortable but not in medical danger. The above signs indicate something has gone wrong — often a drug combination.
Immediate steps:
- Call emergency services if breathing is compromised, person is unresponsive to sternal rub, or any sign of choking
- Place in recovery position (on side, mouth angled downward) to prevent choking
- Clear airway of vomit if present
- Monitor breathing continuously
- Do NOT leave the person alone
- Do NOT induce vomiting
- Do NOT restrain unless immediate physical danger (near traffic, water, heights)
What to tell the dispatcher: Substance taken (ketamine, plus anything else), approximate amount, time of last dose, current symptoms, and whether any other drugs were involved. Good Samaritan laws in many jurisdictions protect callers from prosecution when seeking medical help.
Legal Status[edit]
International framework
Ketamine is not listed under any UN drug control convention; it is controlled entirely through national legislation.[2][36] The WHO has repeatedly recommended international scheduling; the UN Commission on Narcotic Drugs has rejected these recommendations — largely to preserve access in low-resource healthcare settings where ketamine serves as an essential anesthetic.
Jurisdiction table
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule III (Controlled Substances Act) | Classified 1999; medical use as Ketalar (1970) and Spravato (2019) maintained[2][4] |
| United Kingdom | Class B, Schedule 2 (Misuse of Drugs Act 1971) | Reclassified from Class C to Class B in January 2015 |
| Australia | Schedule 8 (Controlled Drug) | Strict prescription requirementscitation needed |
| Canada | Schedule I (CDSA) | Controlled Drugs and Substances Actcitation needed |
| China | Category I psychotropic drug | Since 2004; reflects scale of recreational use in mainland China and Hong Kong[2] |
| European Union | No EU-harmonized scheduling | Member states apply national legislation; most classify equivalent to Schedule II/III controls |
Legal status varies by jurisdiction and changes frequently. Nothing here constitutes legal advice.
references
- [1]
- [2]
- [3] ^abZarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression — Archives of General Psychiatry PMID:16894061
- [4] ^abcdvan Hoogdalem MW, Fu DJ, Drevets WC, Zannikos PN (2026) Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science — Clinical and Translational Science doi:10.1111/cts.70527
- [5] ^abSeeman P, Ko F, Tallerico T (2005) Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics — Molecular Psychiatry PMID:15852061
- [6] ^abCosci F, Chouinard G (2020) Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications — Psychotherapy and Psychosomatics doi:10.1159/000506868